The Russian Direct Investment Fund (RDIF) expects the World Health Organization (WHO) to approve the Sputnik V coronavirus vaccine by the end of 2021. The corresponding statement was made by Kirill Dmitriev the head of the fund, on Bloomberg TV on Tuesday, November 16.
“We are maintaining a dialogue with the WHO. The Ministry of Health is in charge of this process. We expect the approval of the Sputnik V vaccine by the end of the year,” Dmitriev said.
According to him, Russia is successfully using the drug, and no complaints have been received in respect of the safety and effectiveness of the vaccine. More than 100 million people outside the Russian Federation have been vaccinated with Sputnik V and Sputnik Lite. The delivery of vaccines proceeds in accordance with the schedule.
“We expect that we will be able to occupy 15-20% of the market in middle-income countries,” said the head of the RDIF.
Data on the use of Sputnik V in Argentina, San Marino, Serbia, Hungary, Bahrain, Mexico, the UAE, the Philippines, and other countries demonstrate that Sputnik V is one of the safest and most effective vaccines against coronavirus.
Now the Sputnik Lite vaccine, due to its high safety and effectiveness, is not only used in stand-alone mode in some countries, but its action in combination with drugs from other manufacturers is also studied.
Sputnik V was registered in Russia on August 11, 2020. It became the world’s first officially registered COVID-19 vaccine. Now the drug is registered in 71 countries with a total population of four billion people. On March 4, the EU regulator announced that the rolling review procedure for Sputnik V had begun.
